| Identification | Back Directory | [Name]
2-bromolysergic acid diethylamide | [CAS]
478-84-2 | [Synonyms]
BOL
BOL-148
BromLSD
Bromo-LSD
2-bromo-lsd
Bromolysergide
Bromlysergamide
2-bromo LSD (solution)
2-Bromo-LSD 2-Bromo-LSD
2-bromolysergic acid diethylamide
D-2-Bromolysergic acid diethylamide
2-Bromo-D-lysergic acid diethylamide
(8β)-2-Bromo-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
Ergoline-8-carboxaMide,2-broMo-9,10-didehydro-N,N-diethyl-6-Methyl-, (8b)-
Ergoline-8-carboxamide, 2-bromo-9,10-didehydro-N,N-diethyl-6-methyl-, (8β)- | [Molecular Formula]
C20H24BrN3O | [MDL Number]
MFCD01746231 | [MOL File]
478-84-2.mol | [Molecular Weight]
402.34 |
| Chemical Properties | Back Directory | [Melting point ]
120-127° | [alpha ]
D20 +15° (c = 0.5 in pyridine); D20 +53° (c = 0.5 in chloroform) | [density ]
1.3040 (rough estimate) | [refractive index ]
1.6770 (estimate) | [solubility ]
DMSO: Soluble: =10 mg/ml
Ethanol: Soluble: =10 mg/ml | [Boiling point ]
580.7±50.0 °C(Predicted) | [form ]
Solid | [pka]
15.65±0.40(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation[1]. | [in vivo]
2-Bromo-LSD (0.125-5.5mg/kg; i.p.; single dose) increases the in vivo tyrosine hydroxylation in the striatum of Male Sprague-Dawley rats, and increase the accumulation of DOPA with minimum effect dose of 0.125 mg/kg[1].
| [References]
[1] Persson SA. The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats. Eur J Pharmacol. 1977 May 1;43(1):73-83. DOI:10.1016/0014-2999(77)90162-5 |
|
|